HomeTagsTeclistamab

teclistamab

Biotechnology

Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses

Business Wire - June 9, 2022

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study.1 Teclistamab is an...

Healthcare

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple...

PR Newswire - December 14, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the MajesTEC-1...